News

William Garner, president and CEO of Urigen, said: “Urigen’s development program with Hyaluron is a critical step forward for URG101. We look forward to working with the drug

The submitted ANDA is a drug product that is given as a treatment for many different types of cancer, and Akorn expects to launch the drug product in

The pending patent covers systemic therapeutic agents that are used in conjunction with visible light for photodynamic treatment of cancer, skin diseases, and other tissue disorders. The active

Amlodipine is indicated for the treatment of hypertension, for the symptomatic treatment of chronic stable angina, and for the treatment of confirmed or suspected vasospastic angina. Amlodipine is

The two identical Phase III trials, Impact I and Impact II, were randomized, double-blind, placebo-controlled trials conducted at over 60 centers across the US. The studies enrolled 367

This patent protects a process of obtaining avian embryonic stem cells modified through homologous recombination to express recombinant proteins of interest. The new patent strengthens the company’s portfolio

The Phase II clinical trial is a single arm, multicenter study to evaluate the safety and efficacy of treatment with CoFactor plus 5-fluorouracil (5-FU) in advanced breast cancer

Both compounds are proprietary Delta opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions. The terms of the

Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.